Intellia Therapeutics (NTLA) Tops Q1 EPS by 17c

Intellia Therapeutics (NASDAQ: NTLA) reported Q1 EPS of ($1.10), $0.17 better than the analyst estimate of ($1.27). Revenue for the quarter came in at $16.63 million versus the consensus estimate of $12.79 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Lowe's (LOW) PT Lowered to $275 at Guggenheim
• H.C. Wainwright Reiterates Buy Rating on Lifeward (LFWD)